Atkinson Edward Morrow III's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 26, 2025
- Accession no.
- 0000875320-25-000107
- Filed
- Feb 26, 2025
- Trade date
- Feb 24-25, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $849.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atkinson Edward Morrow IIICIK 0001914164 | Officer (EVP, Chief Technical Ops. Off.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2025 | Common Stock | FTax withholdingDisposed | −1,656 | $483.28 | −$800,311.68 | 26,251 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −1,767 | $480.95 | −$849,838.65 | 24,484 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.